Regional Analysis

Global Anti-Obesity Drug Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global anti-obesity drug market over the forecast period due to the increasing burden of obesity and related chronic diseases and the increase in demand for anti-obesity drugs in the region. North America holds 42.1% of the market share. For instance, obesity in the U.S. is common and is a major health issue associated with numerous diseases, such as cancer, diabetes, and cardiovascular disease. Trust for America's Health's (TFAH) 19th annual report on the nation’s obesity, State of Obesity 2022: Better Policies for a Healthier America found that four in ten American adults have obesity, and obesity rates continue to climb nationwide.

Figure 2. Global Anti-Obesity Drug Market Value (US$ Million), By Region, 2023

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa